Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Mar;19(3):1099-1100.
doi: 10.1002/alz.12863. Epub 2022 Nov 16.

Comment on "Effect of reduction in brain amyloid levels on change in cognitive and functional decline in randomized clinical trials: An updated instrumental variable meta-analysis"

Sarah F Ackley  1 , M Maria Glymour  1
Affiliations
Comment

Comment on "Effect of reduction in brain amyloid levels on change in cognitive and functional decline in randomized clinical trials: An updated instrumental variable meta-analysis"

Sarah F Ackley et al. Alzheimers Dement. 2023 Mar.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Disclosures: Both authors have nothing to disclose.

Comment in

Comment on

References

    1. Ackley SF, Zimmerman SC, Brenowitz WD, Tchetgen EJT, Gold AL, Manly JJ, et al. Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis. BMJ. 2021. Feb 25;372:n156. - PMC - PubMed
    1. Mullane K, Williams M. Alzheimer’s therapeutics: Continued clinical failures question the validity of the amyloid hypothesis—but what lies beyond? Biochemical Pharmacology. 2013. Feb 1;85(3):289–305. - PubMed
    1. Thornton A, Lee P. Publication bias in meta-analysis: its causes and consequences. Journal of Clinical Epidemiology. 2000. Feb 1;53(2):207–16. - PubMed
    1. Howard R, Liu KY. Questions EMERGE as Biogen claims aducanumab turnaround. Nature Reviews Neurology. 2020. Feb;16(2):63–4. - PubMed
    1. Swanson CJ, Zhang Y, Dhadda S, Wang J, Kaplow J, Lai RYK, et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody. Alz Res Therapy. 2021. Apr 17;13(1):80. - PMC - PubMed

LinkOut - more resources